Amylyx Pharmaceuticals (NASDAQ:AMLX) versus Corbus Pharmaceuticals (NASDAQ:CRBP) Financial Contrast

Corbus Pharmaceuticals (NASDAQ:CRBP) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Corbus Pharmaceuticals and Amylyx Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2	0	8	1	2.73
Amylyx Pharmaceuticals	1	2	9	1	2.77

Corbus Pharmaceuticals currently has a consensus price target of $42.33, suggesting a potential upside of 264.79%. Amylyx Pharmaceuticals has a consensus price target of $23.00, suggesting a potential upside of 67.39%. Given Corbus Pharmaceuticals’ higher probable upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Valuation and Earnings

This table compares Corbus Pharmaceuticals and Amylyx Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54 million	($5.82)	-1.99
Amylyx Pharmaceuticals	$87.37 million	17.49	-$144.74 million	($1.50)	-9.16

Corbus Pharmaceuticals has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Corbus Pharmaceuticals has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

Insider and Institutional Ownership

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Amylyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Corbus Pharmaceuticals and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Summary

Amylyx Pharmaceuticals beats Corbus Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.